Tvardi Therapeutics 3Q 2026: EPS ($0.48) — 10-Q Summary

Tvardi Therapeutics reported a widened net loss of $6.12M for 3Q 2026, up 10.8% YoY, driven by higher R&D costs, particularly for the TTI-101 HCC trial. Diluted EPS was ($0.48). The company had no revenue. TTI-109 showed promising Phase 1 results, with plans to target ulcerative colitis.

Original reporting
Published Nov 13, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tvardi Therapeutics 3Q 2026: EPS ($0.48) — 10-Q Summary — source image
Decision brief

The 30-second read

$TVRDBearishLow
01

Why it matters

The earnings miss and higher cash burn suggest short‑term downside, but the clinical progress may offer long‑term catalysts.

02

Market read

The filing provides fresh loss and trial‑cost data, likely prompting a sell‑off in TVRD.

03

What to watch

Potential future partnership or licensing deals for TTI‑101 could offset near‑term losses.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Tvardi Therapeutics filed its Q3 2026 10‑Q, reporting no revenue and increased R&D spend on its lead candidates.

Company-level read

Ticker impact

$TVRDBearishHigh confidence
Context

10-Q shows widened net loss and higher R&D spend on TTI-101 trial.

Expected impact

downward pressure as investors price in higher loss and cash burn

Evidence & confidence

Loss widened 10.8% YoY and EPS fell to -$0.48, with no revenue and increased trial costs.

Market effects

Biotech sector may see broader risk aversion on early‑stage trial cost escalations.

US biotech investors likely to reassess exposure to cash‑burn heavy pipelines.

Limited; impact confined to small‑cap biotech investors.

Counterpoint

If the trial data eventually prove successful, the stock could rebound on long‑term upside.

Key entities

  • Tvardi Therapeutics

    US‑listed biotech developing TTI‑101 and TTI‑109.

Related articles

$TVRDMed

Tvardi Therapeutics Reports Q3 2026 Net Loss of $6.1 Million

Tvardi Therapeutics reported a Q3 2026 net loss of $6.1M, up from $5.5M a year earlier. R&D expenses rose to $4.5M, while G&A expenses fell to $1.9M. The company had $22.3M in cash and expects funds to last into Q3 2027. Tvardi is preparing to advance TTI-109 into clinical trials for ulcerative colitis and expects Phase 1b/2 REVERT LIVER CANCER study results in early Q1 2027.

$TVRDMed

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ​ ​ Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update HOUSTON, TX – November 13, 2026 – Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of

$TVRDMed

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics, Inc. (TVRD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immu

$TVRDMedAI 8/10

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

Tvardi Therapeutics (NASDAQ: TVRD) reported Phase 1 results for its oral STAT3 inhibitor TTI-109. The company said TTI-109 rapidly converts to TTI-101, shows dose-proportional pharmacokinetics with exposures above the STAT3 IC50, and reduced STAT3-driven immune cell populations by up to 60% in exploratory analyses. It also cited shorter diarrhea duration vs TTI-101. TVRD shares rose sharply on the news.

$TVRDMed

Tvardi's TTI-109 Shows Improved Tolerability And Target Engagement In Phase 1 Study

Tvardi Therapeutics (TVRD) reported Phase 1 results for TTI-109, a phosphate prodrug of TTI-101. The drug converted rapidly and showed plasma exposure similar to TTI-101 at equivalent doses, with repeat dosing maintaining levels above the STAT3 inhibitory threshold for 21 days. Exploratory data showed up to 60% reductions in STAT3-driven immune cells and shorter diarrhea duration vs TTI-101. Phase 2 is planned pending funding.

$TVRDMedAI 8/10

Why Is Tvardi Therapeutics Stock Gaining Tuesday? - Tvardi Therapeutics (NASDAQ:TVRD)

Tvardi Therapeutics (NASDAQ:TVRD) reported Phase 1 results for TTI-109, a STAT3 inhibitor prodrug. The company said TTI-109 converted to TTI-101 within two hours, showed dose-proportional pharmacokinetics and target engagement, and had diarrhea events comparable to placebo (0.46 vs 3.35 days vs near-equivalent TTI-101). Shares rose ~49.75% to $3.01; plans to advance into dermatologic and gastrointestinal indications pending IND clearance and funding.